Skip to main content
University of Wisconsin-Madison

Drug developed by Kwon receives granted orphan designation by FDA

Co-D Therapeutics, Inc., a pre-clinical stage pharmaceutical company developing agents for the treatment of cancer, was granted orphan designation for Triolimus for the treatment of Angiosarcoma. Triolimus technology was developed by Glen Kwon, professor in the Pharmaceutical Sciences Division. He is co-founder and Chief Scientific Officer of Co-D.